PWP
ALNY icon

Perfromance Wealth Partners’s Alnylam Pharmaceuticals ALNY Stock Holding History

Perfromance Wealth Partners’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-725
Closed -$240K – 236
2026
Q1 		$240K Hold
725
– – 0.01% 187
2025
Q4 		$288K Hold
725
– – 0.01% 167
2025
Q3 		$331K Sell
725
-10
-1% -$4.07K 0.01% 158
2025
Q2 		$240K Buy
+735
New +$203K 0.01% 166

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Perfromance Wealth Partners's ALNY Position: Q2 2026 in Review

Perfromance Wealth Partners sold out of Alnylam Pharmaceuticals (ALNY) in Q2 2026, closing a stake of 725 shares — an estimated $240K sold.

Perfromance Wealth Partners first reported a position in ALNY in Q2 2025 and held it in 4 quarters. The position peaked at $331K in Q3 2025. 790 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

  • Perfromance Wealth Partners reported no remaining Alnylam Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Perfromance Wealth Partners sold 725 Alnylam Pharmaceuticals shares in Q2 2026, an estimated $240K.
  • Perfromance Wealth Partners first reported a position in Alnylam Pharmaceuticals in Q2 2025 and held it in 4 quarters.
  • Perfromance Wealth Partners's Alnylam Pharmaceuticals position peaked at $331K in Q3 2025.
  • 790 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on Perfromance Wealth Partners's 13F filing for Q2 2026, filed 7 Aug 2026.